Ovarian Cancer Clinical Trials in West Valley City, Utah

6 studies are recruiting for ovarian cancer in West Valley City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Center for Cancer Research, West Valley City, Utah

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

2. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

   The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjuga…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Mountain Region, West Valley City, Utah

   Locations

   29 in total

   Run by

   Tubulis GmbH

   See if you can join NCT06303505 on ClinicalTrials.gov

3. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Mountain Region, West Valley City, Utah

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

4. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Mountain Region, West Valley City, Utah

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

5. A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer

   Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with bevacizumab, in participants with ovarian cancer. ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Start Mountain Region /ID# 278609, West Valley City, Utah

   Locations

   17 in total

   Run by

   AbbVie

   See if you can join NCT07278336 on ClinicalTrials.gov

6. Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

   The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Mountain Region, West Valley City, Utah

   Locations

   3 in total

   Run by

   Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

   See if you can join NCT07517198 on ClinicalTrials.gov